All In Biotech

Drug Trial Radar · NCT01916226

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

Study 200165, A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Compare the Efficacy of a 2-Week Treatment With Fluticasone Propionate Nasal Spray Versus Cetirizine in Adult Subjects With Seasonal Allergic Rhinitis (SAR)

Last checked: Nov 20, 2026Latest source record: Jun 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 682 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

682

Actual

Start

Aug 1, 2013

Primary completion

Oct 1, 2013

Study completion Oct 17, 2013

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Aug 5, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase IV investigational trial is being conducted to evaluate the efficacy of a 2-week treatment of fluticasone propionate nasal spray (FPNS) vs. cetirizine on allergic nasal and ocular symptoms and quality of life in adult subjects with SAR. It is hypothesized that FPNS provides greater nasal symptom relief than cetirizine. The primary measure used to test this hypothesis is the change from baseline over two weeks in reflective total nasal symptom score (rTNSS) compared between FPNS and cetirizine. Approximately 648 subjects will be randomized into a 1:1:1:1 ratio of treatment allocation across approximately twenty-five to thirty-five sites in the US during the 2013 fall allergy season. All subjects will be outpatients. The total duration of study will be approximately 21 days including 7 days of screening period, and 14 days of treatment period.

Conditions

  • Rhinitis, Allergic, Perennial and Seasonal

Interventions

  • FPNSDrug

    Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.

  • FPNS PlaceboDrug

    Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.

  • CetirizineDrug

    Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).

  • Cetirizine PlaceboDrug

    Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline (CFB) in the Individual AM Reflective Total Nasal Symptom Scores (rTNSS) Over the Entire Treatment PeriodTime frame: Baseline through the entire treatment period (2 weeks)

Locations

31 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Denver, Colorado

  • GSK Investigational Site

    Aventura, Florida

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Indianapolis, Indiana

  • GSK Investigational Site

    Lenexa, Kansas

  • GSK Investigational Site

    Overland Park, Kansas

  • GSK Investigational Site

    Owensboro, Kentucky

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Bethesda, Maryland

  • GSK Investigational Site

    North Dartmouth, Massachusetts

  • GSK Investigational Site

    Ypsilanti, Michigan

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Columbia, Missouri

  • GSK Investigational Site

    Rolla, Missouri

  • GSK Investigational Site

    St Louis, Missouri

  • GSK Investigational Site

    Bellevue, Nebraska

  • GSK Investigational Site

    Canton, Ohio

  • GSK Investigational Site

    Cincinnati, Ohio

  • GSK Investigational Site

    Oklahoma City, Oklahoma

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Orangeburg, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Austin, Texas

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Kerrville, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Waco, Texas

  • GSK Investigational Site

    South Burlington, Vermont

  • GSK Investigational Site

    Greenfield, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.